Search company, investor...
Owkin company logo

Owkin

owkin.com

Founded Year

2016

Stage

Corporate Minority | Alive

Total Raised

$334.1M

Last Raised

$80M | 1 yr ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+30 points in the past 30 days

About Owkin

Owkin specializes in artificial intelligence technologies applied to clinical research and developing drugs and treatments for patients. The company empowers researchers in hospitals, universities, and the biopharma industry to understand drug efficacy varies, improve the drug development process, and help identify key drugs and treatments for individual patients to improve patient outcomes. The company delivers a medicine platform that aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The company was founded in 2016 and is based in New York, New York.

Headquarters Location

831 Broadway Unit 3R

New York, New York, 10003,

United States

Missing: Owkin's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing Owkin

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTH ➡MARKET STRENGTH ➡LEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare & Life Sciences / Health Data & Analytics

The real-world data market refers to the collection and analysis of data from various sources, including electronic health records, claims data, and patient-generated data. This data is used to provide insights into real-world patient outcomes, treatment patterns, and disease progression. The market offers solutions that can help healthcare stakeholders make informed decisions about drug developme…

Owkin named as Outperformer among 14 other companies, including Tempus, Syapse, and Aetion.

Missing: Owkin's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Owkin

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Owkin is included in 14 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,208 items

C

Clinical Trials Tech

341 items

Companies developing products and services to streamline drug R&D, from drug discovery, pre-clinical testing, and clinical trials.

A

AI 100

400 items

A

Artificial Intelligence

10,622 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

B

Biopharma Tech

6,405 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Owkin Patents

Owkin has filed 4 patents.

The 3 most popular patent topics include:

  • Artificial neural networks
  • Classification algorithms
  • Machine learning
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/23/2021

1/24/2023

Machine learning, Artificial neural networks, Classification algorithms, Statistical classification, Histopathology

Grant

Application Date

2/23/2021

Grant Date

1/24/2023

Title

Related Topics

Machine learning, Artificial neural networks, Classification algorithms, Statistical classification, Histopathology

Status

Grant

Latest Owkin News

A deep tech investor predicts these 3 AI startups will become the decacorns of this decade with valuations of over $100 billion

May 1, 2023

download the app Email address By clicking “Sign Up,” you also agree to marketing emails from both Insider and Morning Brew; and you accept Insider’s Terms and Privacy Policy . Click here for Morning Brew’s privacy policy. As a venture capitalist in the deep tech sector and the managing partner at MARL Accelerator, I've reviewed over 5,000 early-stage companies and have been exposed to the latest technological advancements over the past few years. With the way technology is advancing, things that exist now were once science fiction in the 80s and 90s. These technologies will continue to shape our world and enhance our lives in ways that we can't yet fathom. Amir Khan is the founder and managing director of MARL 5G Accelerator. Amir Khan By 2030, I think there will be a significant increase in the development of artificial intelligence (AI) and machine learning (ML) technologies in the commercial sector. One of the most notable advancements is the rise of Natural Language Processing technologies such as OpenAI's ChatGPT and Google's BARD , which I have been following for almost 10 years. There are a few startups at the forefront of technology in their respective sectors that I believe have the potential to be the decacorns — a company valued over $100 billion — of this decade. I'm not invested in any of these. I missed the boat, but if I had the cash years ago, I would've invested. 1. Owkin A health tech startup called Owkin , based in Paris, France, is working to build an AI model in partnership with top academic researchers and data scientists. By studying millions of patients' data, they hope to find patterns in disease diagnosis and develop new treatments tailored to each patient's genetic makeup. Because we rely on human doctors, there's a risk of misdiagnosis and mistreatment. This issue is near and dear to me because I have been misdiagnosed many times — and I'm not alone. According to The Leapfrog Group , a national watchdog organization focused on healthcare safety, diagnostic errors contribute to 40,000 - 80,000 deaths per year in the US, and over 250,000 Americans experience a diagnostic error in hospitals. Owkin started working on healthcare diagnostics in the mid-2000s, and they're ahead of the pack even though there is substantial research in this area. The development of new technology, like Owkin's platform for medical research, can have downsides as well as benefits. For one, Owkin's platform may be affected by data bias, meaning the models created may be biased or incomplete, despite their efforts to use diverse data. Additionally, only a limited number of researchers and institutions have access to Owkin's platform, which could be costly, and regulatory and ethical challenges need to be addressed to ensure data privacy, security, and compliance. Owkin will need to operate transparently and ethically to address concerns related to patient consent and transparency while navigating complex regulations. 2. Motional Motional is a Boston-based autonomous tech startup that is gaining traction by successfully running the world's first robotaxi pilot program. Motional has completed over 100,000 self-driving rides without any accidents as of 2021. This success has excited Uber, leading to the announcement of a 10-year commercial partnership between the two companies to launch their public full self-driving robotaxi service in Las Vegas, NV. This service follows the successful launch of autonomous deliveries with Uber Eats in Greater Los Angeles. I grew up in India, and self-driving seemed like a dream. If you've seen the old Batman movies, you would know self-driving vehicles were promised to us in the early 2000s. Even today, we're not quite there yet — the technology isn't fully developed. And I think the reason for that is that the car itself doesn't have enough processing power. But I think the evolution of 5G technology may change that. Motional is already performing successfully and securing partnerships. They have changed the game in commercialization. As amazing as Motional sounds, there are some concerns that need to be addressed before the technology can be widely adopted. Safety is one of the biggest concerns, although Motional's technology has been shown to be safe in testing. Driverless vehicles are also vulnerable to cyberattacks. Cost is another concern, as Motional's vehicles are currently expensive to produce and not yet affordable for most people. Lastly, there are ethical concerns, such as who is responsible if a driverless vehicle causes an accident. While Motional has a lot of potential, these shortcomings need to be addressed before the technology can be widely adopted. 3. Nexar Nexar , a New York-based startup, is also a company working to realize our self-driving car dreams. It is a leader in the dash cam market and has the vision of creating the world's first "safe driving network." They plan to build a hive mind by connecting all the dash cams already on the road to provide a single source of truth for events that occur on the road. So the car can see what the car in front of me is seeing, what the car behind me is seeing in a "hive mind." The car network sensors simultaneously plug into a cloud sending data and receiving data. That is why Nexar will be able to succeed in cities. like New York and San Francisco, while vehicles like the Tesla tend to freeze in these kinds of areas. The points of concern regarding Nexar's autonomous driving technology are that it is still under development and not yet fully autonomous. While Nexar's dash cams can identify dangerous situations, they cannot drive the car autonomously. The technology is expensive and may have bugs that need to be fixed. It is also important to check local regulations before using it, as its legality is not yet established in all jurisdictions. AI will change our lives in other areas too But I'm only scratching the surface of AI and Machine learning capabilities and how they will transform our lives. Their impact will go far beyond the healthcare and transportation sectors. For example, we are facing a huge climate crisis, and AI could be our last hope to reverse the effects of climate change. Amir Khan is the founder and managing director of MARL 5G Accelerator. MARL 5G focuses on creating and connecting early-stage investors, startup founders, and corporate venture teams in the space of mobility, autonomy, robotics and logistics. Sign up for notifications from Insider! Stay up to date with what you want to know. Subscribe to push notifications

Owkin Frequently Asked Questions (FAQ)

  • When was Owkin founded?

    Owkin was founded in 2016.

  • Where is Owkin's headquarters?

    Owkin's headquarters is located at 831 Broadway, New York.

  • What is Owkin's latest funding round?

    Owkin's latest funding round is Corporate Minority.

  • How much did Owkin raise?

    Owkin raised a total of $334.1M.

  • Who are the investors of Owkin?

    Investors of Owkin include Bristol-Myers Squibb, Sanofi Ventures, EIT Health Gold Track, Plug and Play Accelerator, Bpifrance and 11 more.

  • Who are Owkin's competitors?

    Competitors of Owkin include Unlearn, Holmusk, Apheris, nference, Decentriq, Tempus, Scailyte, Bio-AI Health, WhiteLab Genomics, Lunit and 32 more.

Compare Owkin to Competitors

P
Paige

Paige delivers AI-integrated digital diagnostics solutions and biomarkers for pathologists, oncologists, and the research and development community. It works with biopharma companies to create custom diagnostic solutions and drug development technologies to improve patient care. The firm's target customers include pathologists, hospital leads, and chairs as well as life sciences research and translational teams. The company was founded in 2017 and is based in New York, New York.

PathAI Logo
PathAI

PathAI provides AI-powered research tools and services for pathology. PathAI's platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning. PathAI was founded in 2016 and is based in Boston, Massachusetts.

Tempus Logo
Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine-learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions. It serves clients in the healthcare sector. The company was founded in 2015 and is based in Chicago, Illinois.

Evidation Logo
Evidation

Evidation operates as a multichannel health tracking platform. It enables users to connect with multiple appications to track everyday activity and earn rewards for steps, sleep, surveys, and more. The company was founded in 2012 and is based in San Mateo, California.

Aitia Logo
Aitia

Aitia is a health tech company using Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology, neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’sDisease, with several more in development. Aitia’s partners include pharmaceutical companies, academic research and medical centers, medical societies, multi-omic data companies, and patient advocacy groups globally. Aitia was formerly GNS Healthcare and rebranded in January 2023. Aitia was founded in 2000 and is based in Somerville, Massachusetts.

Atomwise Logo
Atomwise

Atomwise uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.